Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

AIDS

Volumn 13, Issue 4, 1999, Pages 465-471

  Gervasoni, Cristina ^c   Ridolfo, Anna Lisa ^c   Trifirò, Giuliana ^c   Santambrogio, Sara ^c   Norbiato, Guido ^c   Musicco, Massimo ^a   Clerici, Mario ^c   Galli, Massimo ^b   Moroni, Mauro ^c  

^a CNR   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NONE

Author keywords

Combined antiretroviral therapy; Fat redistribution; Women

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADIPOSE TISSUE; ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DRUG COMBINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MIDDLE AGED;

ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0033545441     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199903110-00004     Document Type: Article

References (18)

1. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
2. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
3. Mouton Y, Aliandari S, Valette M, et al.: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997, 11:F101-105.
4. Reinhard Brodt H, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB: Changing incidence of AIDS-defining illness in the era of antiretroviral combination therapy. AIDS 1997, 11:1731-1738.
5. Hogg RS, Rhone SA, Yip B, et al.: Antiviral effect of double and triple drug combinations amongst HIV-infected adults; lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998, 12:279-284.
6. Mehta S, Moore RD, Graham NMH: Potential factors affecting adherence with HIV therapy. AIDS 1997, 11:1665-1670.
7. Hengel RL, Watts NB, Lennox II : Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997, 350:1596.
8. Ruane PJ: Atypical accumulation of fatty tissue. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract 1-185].
9. Herry I, Bernard L, de Truchis P, Perronne C: Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997, 25:937-938.
10. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M: 'Buffalo hump' in men with HIV-1 infection. Lancet 1998, 351:867-870.
11. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J: Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:870-875.
12. Viraben R, Aquilina C: Indinavir-associated lipodystrophy, AIDS 1998, 12:F37-39.
13. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodistrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-58.
14. Lui A, Karter D, Turett G: Another case of breast hypertrophy in a patient treated with indinavir. Clin Infect Dis 1998, 26:1482.
15. + persons receiving protease inhibitor therapy: incidence, risk and endocrinologic evaluation. Fifth Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998 [abstract 408].
16. Dong K, Flynn MM, Dickinson BP, et al.: Changes in body habitus in HIV(+) women after initiation of protease inhibitor therapy. 12th World AIDS Conference. Geneva, June 1998 [Abstract 12373].
17. Saint-Marc T, Touraine JL: 'Buffalo hump' in HIV-1 infection. Lancet 1998, 352:319-120.
18. Carr A, Samaras K, Chisholm DJ, Cooper DA: Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodistrophy, hyperlipidaemia and insulin resistance. Lancet 1998, 352:1881-1883.